Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Kristie A. Blum, Jorge Romaguera et al.|New England Journal of Medicine|2013Cited by 1.7k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael Wang, Simon Rule, Kristie A. Blum et al.|Blood|2015Cited by 408
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kristie A. Blum, Kami J. Maddocks et al.|Blood|2016Cited by 289
Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 StudyMichael Wang, Kristie A. Blum, Simon Rule et al.|Blood|2014Cited by 16